Current management of low-grade gliomas.

Fiche du document

Auteurs
Types de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1097/WCO.0000000000000390

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/27676279

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1473-6551

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_AA45A63A4CB17

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer

Mots-clés 0

Antineoplastic Agents, Alkylating/therapeutic use; Brain Neoplasms/diagnosis; Brain Neoplasms/drug therapy; Brain Neoplasms/genetics; Brain Neoplasms/therapy; Combined Modality Therapy; Dacarbazine/analogs & derivatives; Dacarbazine/therapeutic use; Disease-Free Survival; Glioma/diagnosis; Glioma/drug therapy; Glioma/genetics; Glioma/therapy; Humans; Mutation; Prognosis; Treatment Outcome

Sujets proches En

Therapy

Citer ce document

A.F. Hottinger et al., « Current management of low-grade gliomas. », Serveur académique Lausannois, ID : 10.1097/WCO.0000000000000390

Métriques

Partage / Export

Résumé 0

The management of patients suffering from low-grade gliomas (LGGs) remains a challenge in absence of a definite curative therapy. The median survival is highly variable, from 2 years (high-risk disease) to over 15 years (low risk). The aim of this review is to provide a practical step-by-step evaluation of the available treatment options for patients with LGGs. Next to clinical prognostic markers, both the isocitrate dehydrogenase (IDH) mutation status and the status of 1p/19q codeletion are key prognostic factors for the optimal management of patients with LGG. Two recent randomized phase III clinical trials were performed in LGGs. They first compared the efficacy of radiation versus temozolomide (TMZ) chemotherapy in high-risk LGGs. The second trial compared radiation versus radiation combined with procarbazine, lomustine and vincristine chemotherapy. Regarding molecular prognostic factors, IDH wild-type LGGs have the worst prognosis, independent of therapy, whereas patients with mutated IDH, codeleted 1p/19q LGGs fared best regarding progression-free survival (PFS). In high-risk LGGs, PFS is similar regardless of whether patients have been treated with radiation or TMZ. In the second trial, patients who were treated with combination radiation and chemotherapy showed significant longer overall survival.

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en